RBC Life Sciences, Inc.

RBC Life Sciences, Inc.

RBCL
RBC Life Sciences, Inc.US flagOther OTC
0.00
USD
- -
- -
1,549.00Market Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
9.13
9.65
10.76
13.25
14.17
11.37
12.8
12.8
11.32
11.48
12.78
11.01
11.65
11.76
Basic EPS, GAAP
0.27
0.3
0.22
0.83
0.75
-0.15
0.25
-0.03
-0.16
-0.23
-0.27
-0.34
-0.34
-0.11
Free Cash Flow per Basic Share
0.43
0.35
0.79
1.81
-0.68
-0.45
0.17
-0.1
-0.16
0.01
-0.76
-2
- -
0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.21
-3.9
-3.67
-2.79
-1.9
-2.02
-1.75
-1.77
-1.94
-2.17
-2.45
-2.78
-3.12
-3.16
Tangible Book Value per Share
0.97
1.28
1.58
2.51
3.3
3.14
3.42
3.39
3.23
3.03
2.79
2.58
2.24
2.14
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
2
2
2
2
2
Sales/Revenue/Turnover
18
19
22
27
30
25
28
28
25
25
28
24
26
26
Operating Margin (%)
3.56
4.49
4.45
10.72
9.38
-0.64
3.71
-0.25
-3.6
-2.45
-2.21
-10.31
-2.59
-0.53
Depreciation Expense
1
1
1
- -
- -
- -
1
1
1
1
1
1
- -
- -
Net Income, GAAP
1
1
- -
2
2
- -
1
- -
- -
-1
-1
-1
-1
- -
Effective Tax Rate (%)
- -
4.32
38.92
37.06
39.63
- -
37.42
- -
- -
- -
- -
- -
- -
63.73
Profit Margin (%)
2.94
3.06
2.01
6.26
5.31
-1.34
1.98
-0.25
-1.44
-1.96
-2.13
-3.04
-2.93
-0.9
Working Capital
- -
1
2
4
5
5
6
6
5
4
3
5
4
4
LT Debt
3
3
3
2
2
2
2
2
1
1
1
- -
- -
- -
Total Equity
4
5
6
8
9
9
10
10
10
9
8
8
7
7
Return on Invested Capital (%)
8.72
10.59
7.05
19.68
16.02
- -
5.67
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-10.22
-12.15
-9.73
-43.75
-65.54
- -
-30.19
- -
- -
- -
- -
- -
- -
12.18
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'16
Mar'17
Jun'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
1
1
1

Working Capital

FRC

in mil. unless spec.
Dec'16
Mar'17
Jun'17
Total Current Assets
8
8
9
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
1
2
1
Inventories
4
4
6
Total Current Liabilities
3
4
5
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.29%
-6.26%
-9.51%
Free Cash Flow
-661.3%
-1,254.79%
-100.15%
Net Income, GAAP
27.28%
97.89%
1.95%
Sales/Revenue/Turnover
2.57%
-1.47%
5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
5
6
5
7
24
2016
5
6
7
7
26
2017
6
6
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.25
-0.11
0.15
- -
-0.34
2016
-0.18
-0.08
0.05
- -
-0.34
2017
0.02
-0.05
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Price
Full Time Employees
89
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
2301 Crown Court Irving TX United States of America 75038
IPO Date
Jan 3, 2000
Business
RBC Life Sciences, Inc. (OTC: RBCL) develops, manufactures, markets and distributes nutritional supplements and personal care products under the RBC Life brand, alongside advanced wound care and pain management solutions through its wholly owned subsidiary MPM Medical; its Nutritional Products segment offers herbs, vitamins, minerals, natural skin/hair/body care items, Stem-Kine dietary supplement, Microhydrin and Microhydrin Plus antioxidants, VitAloe blend, OliViva immune/cardiovascular beverage, Organic Spirulina, NeuroBright cognitive support, Colo-Vada Plus colon cleanser, HydraCel water enhancer, 24 Seven multivitamin/mineral, Immune 360 immune nourisher and Aloe Gelee soothing gel, marketed via independent distributors and licensing in North America, Southeast Asia and Australia; the Medical Products segment provides wound care for pressure/leg ulcers, cuts, burns and abrasions including cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials and Lidocaine hydrogel, plus radiation skin/tissue protection and pain/itch relief products sold under MPM Medical to U.S. hospitals, nursing homes, clinics and pharmacies through medical/surgical dealers and pharmaceutical distributors. Founded in 1988 and headquartered in Irving, Texas, the company targets wellness-seeking consumers and healthcare professionals across more than 30 countries with quality-assured products tested in-house and by independent labs. In January 2020, RBC Life Sciences received US Patent 8357422 for its NeuroBright supplement formulation supporting cognitive function, learning and memory based on an 18-month University of Texas at Dallas animal study demonstrating enhanced psychomotor abilities and longevity in test subjects.

Company News

APIChat
  • Head-To-Head Analysis: Senestech (NASDAQ:SNES) vs. RBC Life Sciences (OTCMKTS:RBCL)

  • Owens & Minor (NYSE:OMI) versus RBC Life Sciences (OTCMKTS:RBCL) Head to Head Survey